Core Points - The company has approved the second unlock period for its stock incentive plan, allowing 119,000 shares to be released from restrictions on August 4, 2025 [1][21][23] - The stock incentive plan includes two types of restricted stocks, with a total of 1.1 million shares granted, representing 0.73% of the company's total share capital [2][13] - The performance targets for the unlock conditions are based on revenue growth, requiring a minimum increase of 25% for 2023 and 60% for 2024 compared to 2022 [4][17] Summary of the Incentive Plan - The stock incentive plan consists of two categories: first-class and second-class restricted stocks, with 110,000 shares granted in total [2][13] - The first-class restricted stocks have a grant price of 32.00 yuan per share, and the unlock conditions are tied to both company and individual performance assessments [2][4] - The first unlock period allows for 50% of the shares to be released after 12 months, while the second unlock period allows for another 50% after 24 months [2][5] Performance Assessment - Company-level performance assessment requires achieving specific revenue growth targets, with the first unlock period tied to a 25% increase and the second to a 60% increase [4][17] - Individual performance assessments categorize results into five levels, determining the percentage of shares that can be unlocked based on individual performance [18][19] Legal and Compliance - The company has received necessary approvals and legal opinions confirming compliance with relevant laws and regulations regarding the stock incentive plan [23] - The legal opinion states that the conditions for the second unlock period have been met, and the actions taken are in accordance with the company's articles of association and applicable laws [23]
皓元医药: 上海皓元医药股份有限公司关于2023年限制性股票激励计划第一类限制性股票第二个解除限售期解除限售暨上市公告